StreetInsider.com News Articles

Summit Therapeutics plc (SMMT) PT Lowered to $38 at Stifel, But 'Fundamental Conviction Intact'

Fri, 24 Jul 2026 10:18:15 -0400

(Updated - July 24, 2026 10:18 AM EDT)

Stifel analyst Dara Azar lowered the price target on Summit Therapeutics plc (NASDAQ: SMMT) to $38.00 (from $45.00) while maintaining a Buy rating.

The analyst commented, "Ivonescimab's ability to converge China-western OS HRs in HARMONi with more follow-up is worth reiterating, and management framed it well as a maturity-driven read-through template for the upcoming HARMONi-3-Sq disclosure. We think timing is the nuance here. HARMONilevel maturity is not expected until 2027, while the 2H26 guidance for both PFS and OS remains in place. So, skeptics can question alpha spending (again) on any analysis before the

Summit Therapeutics plc (SMMT) PT Lowered to $38 at Stifel, But 'Fundamental Conviction Intact'

Fri, 24 Jul 2026 10:18:15 -0400

(Updated - July 24, 2026 10:18 AM EDT)

Stifel analyst Dara Azar lowered the price target on Summit Therapeutics plc (NASDAQ: SMMT) to $38.00 (from $45.00) while maintaining a Buy rating.

Summit Therapeutics plc (SMMT) PT Lowered to $38 at Guggenheim

Fri, 24 Jul 2026 07:51:57 -0400

(Updated - July 24, 2026 7:51 AM EDT)

Guggenheim analyst Brad Canino lowered the price target on Summit Therapeutics plc (NASDAQ: SMMT) to $38.00 (from $40.00) while maintaining a Buy rating.

The analyst commented: "Later in 2H26, management still expect to conduct the HARMONi-3 1L squamous NSCLC final PFS analysis and take an early look at OS that should have high-teens months of follow-up that allows for a meaningful interpretation. However, the public topline disclosure after data cleaning could spill into early 2027. The event rate has slowed, which caused the update to this disclosure timing. This protocol has changed so many

Summit Therapeutics plc (SMMT) PT Lowered to $38 at Guggenheim

Fri, 24 Jul 2026 07:51:57 -0400

(Updated - July 24, 2026 7:51 AM EDT)

Guggenheim analyst Brad Canino lowered the price target on Summit Therapeutics plc (NASDAQ: SMMT) to $38.00 (from $40.00) while maintaining a Buy rating.

Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald After Q2 Results

Fri, 24 Jul 2026 06:53:28 -0400

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Summit Therapeutics plc (NASDAQ: SMMT).

The analyst commented, "Summit reported Q2 financials and provided a pipeline update. In terms of financials, the company reported a Q2 Net Loss of $216M and ended the quarter with $691M in cash. More interesting of course is the progress on ivonescimab (PD-1 x VEGF bispecific) as it advances toward data from the global Phase 3 HARMONi-3 trial in 1L sq-NSCLC (ivonescimab + chemo vs. pembro + chemo)."

For an analyst ratings summary and ratings history on Summit Therapeutics plc click here. For more ratings news

Summit Therapeutics (SMMT) Reports In-Line Q2 EPS

Thu, 23 Jul 2026 17:42:06 -0400

Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.28), in-line with the analyst estimate of (GBP0.28).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

Form 8-K Summit Therapeutics Inc. For: Jul 23

Thu, 23 Jul 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260723/26808644.html

Form 8-K Summit Therapeutics Inc. For: Jul 23

Thu, 23 Jul 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260723/26808644.html

Form 424B5 Summit Therapeutics Inc.

Thu, 23 Jul 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260723/26808620.html

Form 424B5 Summit Therapeutics Inc.

Thu, 23 Jul 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260723/26808620.html

Summit Therapeutics: substantial doubt about our ability to continue as a going concern

Thu, 23 Jul 2026 16:25:13 -0400

From Summit Therapeutics' (NASDAQ: SMMT) 10-Q filing on Thursday:

During the three and six months ended June 30, 2026, we incurred a net loss of $215.7 million and $405.1 million and cash flows used in operating activities for the six months ended June 30, 2026 was $263.4 million. As of June 30, 2026, we had an accumulated deficit of $2,699.3 million, cash and cash equivalents of $419.4 million and short-term investments of $271.3 million. We expect to continue to generate operating losses for the foreseeable future.

Our cash and cash equivalents and short-term investments are not sufficient to fund our planned

Summit Therapeutics: substantial doubt about our ability to continue as a going concern

Thu, 23 Jul 2026 16:25:13 -0400

From Summit Therapeutics' (NASDAQ: SMMT) 10-Q filing on Thursday:

Our cash and cash equivalents and short-term investments are not sufficient to fund our planned

Form 10-Q Summit Therapeutics Inc. For: Jun 30

Thu, 23 Jul 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260723/26808109.html

Form 10-Q Summit Therapeutics Inc. For: Jun 30

Thu, 23 Jul 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260723/26808109.html

Form 8-K Summit Therapeutics Inc. For: Jul 23

Thu, 23 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260723/26808088.html

Form 8-K Summit Therapeutics Inc. For: Jul 23

Thu, 23 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260723/26808088.html

Summit Therapeutics posts Q2 loss, reports ivonescimab trial data

Thu, 23 Jul 2026 16:06:21 -0400

Summit Therapeutics Inc. (NASDAQ: SMMT) reported a GAAP net loss of $215.7 million, or $0.28 per share, for the second quarter ended June 30, 2026, compared with a net loss of $565.7 million, or $0.76 per share, in the same period a year earlier. The year-over-year decrease was largely due to a $410.1 million reduction in stock-based compensation expense related to a modification of performance-based stock option awards in the second quarter of 2025.

Non-GAAP operating expenses rose to $151.8 million from $89.6 million in the prior-year quarter, driven by expansion of clinical studies and development costs for its lead drug

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy

Ivonescimab Plus Chemotherapy Achieves Statistically Significant and Clinically Meaningful Overall Survival Benefit in 1L Squamous NSCLC HARMONi-6 Trial Conducted in China, the First Phase III Head-to-Head Clinical Study to Demonstrate Superiority over an Anti-PD-(L)1 Antibody-Containing Regimen

HARMONi-3 Global Phase III 1L NSCLC Study: Squamous Cohort Final PFS Analysis Events Expected to Be Reached in Second Half of 2026 with Interim OS Analyses Planned; Non-Squamous Cohort PFS Events Expected to Be Reached in

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy
Ivonescimab Plus Chemotherapy Achieves Statistically Significant and Clinically Meaningful Overall Survival Benefit in 1L Squamous NSCLC HARMONi-6 Trial Conducted in China, the First Phase III Head-to-Head Clinical Study to Demonstrate Superiority over an Anti-PD-(L)1 Antibody-Containing Regimen
HARMONi-3 Global Phase III 1L NSCLC Study: Squamous Cohort Final PFS Analysis Events Expected to Be Reached in Second Half of 2026 with Interim OS Analyses Planned; Non-Squamous Cohort PFS Events Expected to Be Reached in

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy
Ivonescimab Plus Chemotherapy Achieves Statistically Significant and Clinically Meaningful Overall Survival Benefit in 1L Squamous NSCLC HARMONi-6 Trial Conducted in China, the First Phase III Head-to-Head Clinical Study to Demonstrate Superiority over an Anti-PD-(L)1 Antibody-Containing Regimen
HARMONi-3 Global Phase III 1L NSCLC Study: Squamous Cohort Final PFS Analysis Events Expected to Be Reached in Second Half of 2026 with Interim OS Analyses Planned; Non-Squamous Cohort PFS Events Expected to Be Reached in

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy
Ivonescimab Plus Chemotherapy Achieves Statistically Significant and Clinically Meaningful Overall Survival Benefit in 1L Squamous NSCLC HARMONi-6 Trial Conducted in China, the First Phase III Head-to-Head Clinical Study to Demonstrate Superiority over an Anti-PD-(L)1 Antibody-Containing Regimen
HARMONi-3 Global Phase III 1L NSCLC Study: Squamous Cohort Final PFS Analysis Events Expected to Be Reached in Second Half of 2026 with Interim OS Analyses Planned; Non-Squamous Cohort PFS Events Expected to Be Reached in

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy
Ivonescimab Plus Chemotherapy Achieves Statistically Significant and Clinically Meaningful Overall Survival Benefit in 1L Squamous NSCLC HARMONi-6 Trial Conducted in China, the First Phase III Head-to-Head Clinical Study to Demonstrate Superiority over an Anti-PD-(L)1 Antibody-Containing Regimen
HARMONi-3 Global Phase III 1L NSCLC Study: Squamous Cohort Final PFS Analysis Events Expected to Be Reached in Second Half of 2026 with Interim OS Analyses Planned; Non-Squamous Cohort PFS Events Expected to Be Reached in

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy
Ivonescimab Plus Chemotherapy Achieves Statistically Significant and Clinically Meaningful Overall Survival Benefit in 1L Squamous NSCLC HARMONi-6 Trial Conducted in China, the First Phase III Head-to-Head Clinical Study to Demonstrate Superiority over an Anti-PD-(L)1 Antibody-Containing Regimen
HARMONi-3 Global Phase III 1L NSCLC Study: Squamous Cohort Final PFS Analysis Events Expected to Be Reached in Second Half of 2026 with Interim OS Analyses Planned; Non-Squamous Cohort PFS Events Expected to Be Reached in

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy
Ivonescimab Plus Chemotherapy Achieves Statistically Significant and Clinically Meaningful Overall Survival Benefit in 1L Squamous NSCLC HARMONi-6 Trial Conducted in China, the First Phase III Head-to-Head Clinical Study to Demonstrate Superiority over an Anti-PD-(L)1 Antibody-Containing Regimen
HARMONi-3 Global Phase III 1L NSCLC Study: Squamous Cohort Final PFS Analysis Events Expected to Be Reached in Second Half of 2026 with Interim OS Analyses Planned; Non-Squamous Cohort PFS Events Expected to Be Reached in

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

Thu, 23 Jul 2026 16:05:00 -0400

Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy
Ivonescimab Plus Chemotherapy Achieves Statistically Significant and Clinically Meaningful Overall Survival Benefit in 1L Squamous NSCLC HARMONi-6 Trial Conducted in China, the First Phase III Head-to-Head Clinical Study to Demonstrate Superiority over an Anti-PD-(L)1 Antibody-Containing Regimen
HARMONi-3 Global Phase III 1L NSCLC Study: Squamous Cohort Final PFS Analysis Events Expected to Be Reached in Second Half of 2026 with Interim OS Analyses Planned; Non-Squamous Cohort PFS Events Expected to Be Reached in